![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
October 13, 2022
This phase 3 study aims to explore whether treatment with a TKI plus blinatumomab may be superior to the usual treatment approach for acute lymphoblastic leukemia
October 13, 2022
A Standing Main Member of ECOG-ACRIN since 1983
October 13, 2022
The phase III PROSPER RCC clinical trial demonstrated that priming the immune system with nivolumab before surgery, then continuing nivolumab, did not improve recurrence-free survival in patients with high-risk renal cell carcinoma
October 13, 2022
Summaries of recently published ECOG-ACRIN research results
October 13, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
August 16, 2022
President Biden to appoint Dr. Monica Bertagnolli as NCI Director; NCI-MATCH trial data leads to FDA drug approval
August 16, 2022
Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation
August 16, 2022
This phase 3 study is using PET/CT imaging to guide treatment for patients with post-prostatectomy biochemical recurrence
August 16, 2022
August 16, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
June 21, 2022
Reflections on the spring conference season, including highlights from the Spring Group Meeting and ASCO's Annual Meeting
June 21, 2022
This single-arm phase 2 study aims to rid patients of residual disease following initial treatment